Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

GLP Pathology for Dermal Toxicity Studies of Topically Applied Biologics and Advanced Therapies

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

GLP Pathology for Dermal Toxicity Studies of Topically Applied Biologics and Advanced Therapies

CELL & GENE | RNA | BIOLOGICS

Frequently Asked Questions (FAQ)

    What are the primary endpoints in a GxP dermal toxicity study?

    A: Key endpoints include macroscopic observations (erythema, edema), microscopic histological evaluations of the application site and draining lymph nodes, and assessments of systemic exposure through analysis of non-target tissue biodistribution.

    How is local irritation differentiated from a specific immune response?

    A: Histology is the definitive tool. Irritation typically presents as non-specific inflammation. An immune response, such as immunogenicity, is characterized by specific cellular infiltrates (e.g., lymphocytes, plasma cells) and requires evaluation by a board-certified pathologist.

    What are standard tissue collection protocols for these studies?

    A: Protocols involve collecting the treated skin site, untreated adjacent skin, regional draining lymph nodes, and a standard set of systemic tissues to evaluate potential absorption and distribution, all performed under rigorous GxP guidelines.

    What are unique pathology considerations for biologics?

    A: Biologics can elicit complex immune responses and have specific on-target/off-tumor effects. Pathology for these modalities often includes specialized techniques like immunohistochemistry (IHC) to identify specific cell types and protein expression patterns.

Executive Summary

Assessing the safety of topically applied biologics requires a GxP-compliant pathology program that extends beyond simple skin irritation analysis. The primary challenge is characterizing potential systemic absorption and subsequent non-target tissue effects, which can present significant hurdles to achieving a successful IND submission. A robust histological evaluation provides the definitive data to differentiate local reactions from systemic liabilities, directly informing dose selection and risk mitigation strategies for clinical development.

A 3D rendering of Y-shaped antibody molecules against a blue, abstract background.

A close-up of a scientist in a lab, wearing blue gloves and examining the results of a gel electrophoresis or Western blot.

The Challenge of Localized Delivery and Systemic Risk

For advanced therapies applied dermally, including RNA-based constructs and viral vectors, the assumption of purely localized action is a liability. While the intended therapeutic site is the skin, unintended systemic exposure can lead to unforeseen toxicities in distal organs. This risk reflects a foundational principle in advanced therapy development, where payload delivery can have unintended consequences.

Published investigations into systemic AAV administration, for example, have documented severe toxicities in non-target sensory neurons (PMID: 29378426). Similarly, studies using AAV-delivered shRNA have demonstrated significant cardiac toxicity despite a targeted therapeutic goal (PMID: 21542669). These findings underscore a key translational insight: a therapy’s delivery mechanism and payload can interact with biological systems in unexpected ways. For dermal applications, this necessitates a rigorous pathology program to confirm the biologic remains localized or to accurately characterize the consequences if it does not.

Board-Certified Pathology for IND-Enabling Studies

At Franklin Biolabs, our GxP-compliant histology and pathology services are designed to provide clear, actionable data for your IND submission. Our team of board-certified pathologists specializes in the unique challenges presented by biologics and advanced therapies. We provide clear differentiation between expected local inflammatory responses and adverse findings indicative of systemic risk.

Our program operates within a >100,000 sq ft facility, leveraging a deep understanding of regulatory expectations to support an 18-24 month average IND timeline for our partners. This focused approach has contributed to a 100% IND success rate for all programs conducted since 2019. (The Franklin Biolabs brand launched in 2024. By providing definitive histological data, we deliver rapid pathology insights accelerating preclinical readouts.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities